Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.

20 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Merck announces changes in vorapaxar clinical studies

Merck today provided the following statement on the changes to the clinical studies for vorapaxar, one of the Company's investigational cardiovascular medicines, following an announcement from the two academic centers leading the studies of vorapaxar.

14 Jan 2011

Cholesterol efflux capacity is more closely associated with protection against heart disease: Study

The discovery that high levels of high-density lipoprotein cholesterol is associated with reduced risk of cardiovascular disease has fostered intensive research to modify HDL levels for therapeutic gain. However, recent findings have called into question the notion that pharmacologic increases in HDL cholesterol levels are necessarily beneficial to patients.

13 Jan 2011

Plenty of breaks from sitting at the desk are good for hearts and waistlines: Study

It is becoming well accepted that, as well as too little exercise, too much sitting is bad for people's health. Now a new study has found that it is not just the length of time people spend sitting down that can make a difference, but also the number of breaks that they take while sitting at their desk or on their sofa. Plenty of breaks, even if they are as little as one minute, seem to be good for people's hearts and their waistlines.

12 Jan 2011

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.

11 Jan 2011

Genetics Squared to change corporate name to Everist Genomics

Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.

10 Jan 2011

FDA grants marketing clearance for diaDexus's PLAC Test

diaDexus, a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced that the U.S. Food and Drug Administration has cleared for marketing the automated version of its proprietary PLAC® Test.

9 Jan 2011

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.

7 Jan 2011

Punch card study reveals link between high-density lipoprotein particles and heart disease

A stack of punch cards from a landmark study published in 1966, and the legwork to track down the study's participants years later, has yielded the longest analysis of the effects of lipoproteins on coronary heart disease.

6 Jan 2011

Columbia research team identifies bacteria may play a key role in atherosclerosis

Dr. Emil Kozarov and a team of researchers at the Columbia University College of Dental Medicine have identified specific bacteria that may have a key role in vascular pathogenesis, specifically atherosclerosis, or what is commonly referred to as "hardening of the arteries" - the number one cause of death in the United States.

6 Jan 2011

Betulin in birch bark appears to provide metabolic benefits

An ingredient found in abundance in birch bark appears to have an array of metabolic benefits, according to new studies in animals that are reported in the January issue of Cell Metabolism, a Cell Press publication.

5 Jan 2011

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

Atherosclerosis is the leading cause of death in the developed world. While a number of risk factors for atherosclerosis have been defined, scientists continue to study other possible risk factors for this disease. Recent epidemiological and experimental studies link infectious agents with the development of inflammatory atherosclerosis. A hallmark of chronic infection with the oral pathogen Porphyromonas gingivalis is the induction of a chronic inflammatory response.

5 Jan 2011

Anaphylatoxin C5a may be responsible for devastating effects of atherosclerosis

For decades, doctors have looked at fitness levels, weight, and overall health risk factors for heart disease and stroke. Now, they may soon add a new risk factor to the list: activation of the complement system. The complement system is usually implicated in immune responses, but now there's a role for it in cardiovascular disease.

5 Jan 2011

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.

3 Jan 2011

Researchers receive $6.78 million NIH grant for community-based study on heart disease

Researchers at the Methodist DeBakey Heart & Vascular Center in Houston were recently awarded a $6.78 million grant from the National Institutes of Health to extend a 23-year-old large-scale, community-based study of heart disease.

27 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Atherosclerosis News and Research

Further Reading

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Endothelial cells may play a role in controlling cancer behavior: New study

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Merck announces changes in vorapaxar clinical studies

Cholesterol efflux capacity is more closely associated with protection against heart disease: Study

Plenty of breaks from sitting at the desk are good for hearts and waistlines: Study

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

Genetics Squared to change corporate name to Everist Genomics

FDA grants marketing clearance for diaDexus's PLAC Test

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Punch card study reveals link between high-density lipoprotein particles and heart disease

Columbia research team identifies bacteria may play a key role in atherosclerosis

Betulin in birch bark appears to provide metabolic benefits

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

Anaphylatoxin C5a may be responsible for devastating effects of atherosclerosis

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Researchers receive $6.78 million NIH grant for community-based study on heart disease

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News